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Abstract
Pancreatic cancer is a highly lethal disease with a ge-
netic susceptibility and familial aggregation found in 
3%-16% of patients. Early diagnosis remains the only 
hope for curative treatment and improvement of prog-
nosis. This can be reached by the implementation of 
an intensive screening program, actually recommended 
for individuals at high-risk for pancreatic cancer de-
velopment. The aim of this strategy is to identify pre-
malignant precursors or asymptomatic pancreatic can-
cer lesions, curable by surgery. Endoscopic ultrasound 
(EUS) with or without fine needle aspiration (FNA) 
seems to be the most promising technique for early de-
tection of pancreatic cancer. It has been described as 
a highly sensitive and accurate tool, especially for small 
and cystic lesions. Pancreatic intraepithelial neoplasia, 
a precursor lesion which is highly represented in high-
risk individuals, seems to have characteristics chronic 
pancreatitis-like changes well detected by EUS. Many 
screening protocols have demonstrated high diagnostic 
yields for pancreatic pre-malignant lesions, allowing 
prophylactic pancreatectomies. However, it shows a 
high interobserver variety even among experienced en-
dosonographers and a low sensitivity in case of chronic 
pancreatitis. Some new techniques such as contrast-en-
hanced harmonic EUS, computer-aided diagnostic tech-
niques, confocal laser endomicroscopy miniprobe and 
the detection of DNA abnormalities or protein markers 
by FNA, promise improvement of the diagnostic yield of 
EUS. As the resolution of imaging improves and as our 
knowledge of precursor lesions grows, we believe that 
EUS could become the most suitable method to detect 
curable pancreatic neoplasms in correctly identified 
asymptomatic at-risk patients.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: In the era of early diagnosis and screening 
programs, endoscopic ultrasound (EUS) represents the 
most promising tool able to identify pancreatic precur-
sor neoplasms in high risk individuals. If compared 
to other imaging techniques, it is highly accurate to 
diagnose small pancreatic cancer and pre-malignant 
lesions, with very low rate of complications and limi-
tations. Here are reported the current role of EUS in 
various international screening programs and its future 
possible developments.
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INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth 
leading cause of  cancer-related death in the western 
world[1,2], with a median age at diagnosis of  71 years and 
45220 new cases and 38460 deaths in 2013 in the United 
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States[3]. In contrast to other causes of  cancer death (lung, 
colorectal, breast and prostate), which have declined in 
the last years, the death rate from PDAC has increased 
during the same time period[4]. It is a highly aggressive 
tumor characterized by an incidence rate almost equaling 
the mortality rate and an overall 5-year survival of  ap-
proximately 5%-6%[1,2]. This dismal prognosis is mainly 
due to the fact that the tumor is characterized by a locally 
advanced or metastic stage at the presentation, low resec-
tion rates and poor response to radiotherapy and chemo-
therapy.
Even though complete resection improves median 
survival, at the time of  diagnosis only 10% to 25% of  
pancreatic cancer patients will be amenable to potentially 
curative resection[5]. Also in this case 5-year survival re-
mains low (10% to 24%)[6,7].
However, longer survival has been reported for com-
plete resection of  early stage tumors thus identifying pa-
tients who have early, small, localized tumors at presenta-
tion could improve this poor overall survival rate[8].
Resection of  small tumors (< 2 cm or T1) improves 
5-years survival (30% to 60%)[9,10]. However it has been 
alluded that the better prognosis is for tumors < 1 cm 
(T1a) with 5-years survival up to 78%[6,11,12].
To date, however, it might be difficult to detect such a 
small pancreas cancer, mainly due the fact that more than 
90% of  PDAC measuring 1 cm or less in diameter are 
asymptomatic. 
Probably the only way to improve survival lies in 
identifying early disease or precursor lesions through a 
screening program of  asymptomatic individuals.
As premalignant stages of  disease have been identi-
fied, and the sensitivity of  pancreatic imaging has im-
proved with endoscopic ultrasound (EUS) and high-reso-
lution magnetic resonance imaging (MRI), early detection 
of  small curable pancreatic cancers and premalignant 
lesions now seems possible[13-16].
Unfortunately, due to the overall low incidence of  
the disease, accounting for 3% of  all new cancer cases 
in the United States and a life-time risk of  1.3% in the 
general population, and the lack of  simple, safe, accurate, 
inexpensive, and non-invasive diagnostic tests for early 
lesions, a widespread screening program does not seem 
feasible at present.
Multiple risk factors for pancreatic cancer development 
have been identified like male gender, obesity, African-
American or Ashkenazi Jewish descent, nickel exposure, 
smoking, lack of  physical activity, and calorie intake[17-20].
Beside them, also members of  a family with a strong 
history of  disease or individuals with inherited pancreatic 
cancer syndromes, carrying a known genetic mutation, 
should be considered at high risk of  developing pancre-
atic cancer (high risk individuals, HRIs)[21-25]. Screening 
of  these high-risk groups seems to be of  benefit since 
genetic susceptibility and familial aggregation are respon-
sible of  3%-16% of  pancreatic cancers[26-28].
These individuals can be divided into two groups: 
those who belong to families in which pancreatic cancer 
affects at least two first-degree relatives without a known 
genetic mutation (familial pancreatic cancer, FPC) and 
those with hereditary syndromes or diseases that predis-
pose to the development of  pancreatic cancer (Table 1).
FAMILIAL PANCREATIC CANCER
The former represents the largest proportion of  heredi-
tary PDAC.
Prospective studies demonstrated an increased risk of  
pancreatic cancer in healthy first degree relatives (FDRs), 
related to the number of  family members affected. This 
risk has been estimated to be 2.3 to 4.5-fold greater in 
individuals with one FDR with pancreatic cancer, 6.4-fold 
greater in individuals with two FDRs with the disease and 
32 to 57-fold greater in individuals with three or more 
FDRs affected[29-32].
Similarly to other familial tumors, the median age 
of  presentation in patients with FPC is up to 20 years 
earlier than in patients with sporadic cancer (49 years vs 
61 years)[33-35] with an ‘‘anticipation phenomenon’’ in the 
affected kindred and a trend to become more severe and 
appear at an earlier age as the disorder is passed from one 
generation to the next[35,36]. Currently, the genetic etiol-
ogy of  most cases of  FPC remains undetermined but 
complex segregation analysis of  these patients has led to 
the discovery of  various candidate pancreatic cancer sus-
ceptibility genes such as BRCA2 (6%-17% of  cases)[37,38], 
partner and localizer of  BRCA2 (PALB2) (1%-4% of  
cases)[39,40] and palladin, even if  mutations of  the latter 
have been identified in normal controls as well[41-43].
Due to the complex nature of  pedigrees, a Mendelian 
risk prediction tool for PDAC, named PancPRO was de-
veloped in 2007.
This is a prediction model for FPC that, using full 
pedigree data and age of  family members, estimates the 
probability that an asymptomatic individual will develop 
the disease[44].
INHERITED PANCREATIC CANCER 
SYNDROMES
Individuals with certain tumor syndromes have a marked 
increase in risk of  developing pancreatic ductal adenocar-
cinoma.
These syndromes are represented by familial atypical 
mole-multiple melanoma, Peutz-Jeghers syndrome, he-
reditary pancreatitis, cystic fibrosis, familial breast-ovarian 
cancer, hereditary non-polyposis colorectal cancer, famil-
ial adenomatous polyposis, Li-Fraumeni syndrome.
Familial atypical mole-multiple melanoma
Familial atypical mole-multiple melanoma (FAMMM) is 
an autosomal dominant disease associated with mutations 
within CDKN2A gene (p16 Leiden)[45,46]. Its inactivation 
is associated with PDAC that was found 13 to 38-fold 
more frequent than expected[46,47], with a cumulative risk 
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by age 75 of  15% to 20%[48,49].
Peutz-Jeghers syndrome 
Peutz-Jeghers syndrome (PJS) is an autosomal dominant 
genetic disease characterized by an increased risk of  vari-
ous neoplasms, including pancreatic cancer[50,51] and it is 
often associated with mutations within STK11 gene, a 
tumor suppressor gene. Patients with PJS have a 132-fold 
increased risk[50] and an 11%-36% cumulative risk of  de-
veloping PDAC with an early age of  onset (average: 40.8 
years)[50,52]. In this kind of  patients, it frequently develops 
through IPMN[23,53].
Hereditary pancreatitis
Hereditary pancreatitis (HP) is an inherited form of  
chronic pancreatitis characterized by mutations within 
PRSS1, PRSS2, SPINK1, CFTR and CTRC genes[54,55]. 
PDAC is often a consequence of  this condition[56,57] inso-
much so resected pancreata from patients with HP fre-
quently demonstrated PanIN-3 lesions (50%)[58]. Patients 
with hereditary pancreatitis have a 53 to 87-fold increase 
risk[57,59] with an age of  onset at 50 years in smokers[60]. 
Lifetime risk is 30% to 75% in patients with paternal in-
heritance[57,59].
Cystic fibrosis
Cystic fibrosis (CF) is a disorder associated with muta-
tions within CFTR gene with an increased risk for PDAC 
(5.3-fold)[61], in fact the histological aspect of  CF associ-
ated lesions is very similar to that of  ‘‘classical’’ chronic 
pancreatitis, characterized by atrophy of  acinar tissue, 
fibrosis, and inflammation[62,63].
Familial breast-ovarian cancer 
Familial breast-ovarian cancer (FBOC) is an autosomal 
dominant inherited disease due to mutations within 
BRCA1 or BRCA2 genes.
The risk of  PDAC among BRCA1 mutation car-
riers is low (2.3-3.6 fold than general population)[64,65]. 
Conversely BRCA2 mutation carriers had a 3.5-10-fold 
increased risk[66,67] and a 5% lifetime risk of  pancreatic 
cancer[67].
Hereditary non-polyposis colorectal cancer 
Hereditary non-polyposis colorectal cancer (HNPCC) 
is an autosomal dominant genetic condition due to the 
inherited mutations in DNA-mismatch repair genes, 
such as MLH1, MSH2, MSH6, PMS2 and EPCAM[68]. 
The estimated relative risk of  pancreatic cancer is 2.3 to 
8.6-fold higher with a lifetime risk of  pancreatic cancer 
(3%-4%)[69,70]. Carriers of  MLH1 mutations have a higher 
risk than carriers of  MSH2 (5.6 vs 2.3)[71].
Familial adenomatous polyposis
Familial adenomatous polyposis (FAP) is an autosomal 
dominant disease of  the colon caused by mutations with-
in the gene APC. Among FAP pediatric carriers, pancre-
atoblastoma may represent an extracolonic manifestation 
of  FAP[72]. The relative risk for pancreatic cancer is 4.5 in 
patients with the syndrome[73] and the lifetime risk 2%[74].
Li-Fraumeni syndrome 
PDAC seems to be a part of  the cancer spectrum of  the 
Li-Fraumeni syndrome (LFS), a disease caused by muta-
tions within TP53 gene[63,75]. It is has been estimated that 
about 1.3% of  these patients show pancreatic cancer[63,76].
PRECURSOR LESIONS
The ideal screening method for HRIs should detect small 
asymptomatic pancreatic cancers and, mainly, benign 
non-invasive precursor lesions, to allows for curative 
surgical resection[77,78]. In fact pancreatic carcinogenesis 
should be intended as a multistep phenomenon with 
progressive changes from the normal pancreatic ductal 
epithelium to infiltrating carcinoma[79].
The other three well known precursor lesions are: 
pancreatic intraepithelial neoplasms (PanINs), intraductal 
papillary mucinous neoplasms (IPMNs) and mucinous 
cystic neoplasms (MCNs)[78-81]. 
Pancreatic intraepithelial neoplasia 
PanINs are usually asymptomatic and are characterized 
by microscopic papillary or flat, noninvasive epithelial 
neoplasms that are usually < 5 mm in diameter and con-
fined to the pancreatic ducts[78,82].
According to the degree of  cytological and archi-
tectural atypia, PanINs are divided into three grades[83]: 
PanIN-1: minimal atypia; flat (PanIN-1A) and papillary 
types (PanIN-1B); PanIN-2: moderate atypia; PanIN-3: 
severe atypia.
The evidence that this kind of  lesions are linked to 
invasive carcinoma is based on clinical associations and 
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Table 1  Genetic diseases associated with pancreatic cancer 
risk
Risk condition Relative 
risk
Risk by 
age 70
Gene
Familial pancreatic cancer PALLD
1 first-degree relative 2.3-4.5 2% BRCA2
2 first-degree relatives 6.4-18 3% PALB2
≥ 3 first-degree relatives 32-57 16%
Familial atypical multiple mole 
melanoma
13-38 15%-20% CDKN2A/p16
Peutz-Jeghers Syndrome 132 11%-60% STK11/LKB1
Hereditary pancreatitis 50-87 30%-75% PRSS1
PRSS2
SPINK1
CTRC
Cystic fibrosis 5.3 <5% CFTR
Familial breast ovarian cancer 3.5-10 5% BRCA2
2.3-3.6 1% BRCA1
Hereditary non-polyposis 
colon cancer
2.3-8.6 3%-4% MLH1
MSH2
MSH6
Familial adenomatous 
polyposis
4.5-5 2% FAP
MUTYH
Li Fraumeni sindrome Unknown Unknown TP53
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PDAC development greater than 10-fold[22,23,77].
This degree of  risk includes family members with ≥ 
3 first-degree relatives with pancreatic cancer and patients 
with hereditary pancreatitis, FAMMM and PJS. 
A screening test should also be performed in indi-
viduals with syndromes associated with pancreatic cancer 
and known high-risk factors, such as cystic neoplasia, 
duct ectasia, diabetes mellitus, smoking history and 
chronic pancreatitis[101]. To evaluate the risk to develop 
pancreatic cancer can be used mathematical models, such 
as the PancPRO model (see above).
No clear consensus was achieved on when to start 
screening. It seems reasonable to start at 40-50 years 
of  age (30 years for PJS) or 10-15 years earlier than the 
younger kindred affected by pancreatic cancer[21,22,96,102].
There is no consensus also on the frequency, because 
evidence on the natural history and rate of  progression 
of  pancreatic cancer in high risk patients is still lacking. 
However, yearly screening seems to be the most suitable 
approach[21,22,36,103] even if  some centers recommend 3 
years intervals in case of  negative screening exam and ab-
sence of  other risk factors associated. A more aggressive 
protocol can be used for patients with abnormal find-
ings at the last screening[52]. In these cases a subsequent 
screening could be done every 3-6 mo[22,103] or every 3-12 
mo[21,36,100].
The majority of  studies have generally used the same 
imaging test for surveillance as for baseline screening, 
while others suggest an alternating use of  MRI/MRCP 
and EUS[36,98](Figure 1).
ROLE OF ENDOSCOPIC 
ULTRASONOGRAPHY
Endoscopic ultrasonography (EUS) is known as a pow-
erful imaging tool for studying pancreatic diseases. In 
particular it has been described as a very accurate imaging 
technique for early detection of  pancreatic cancer provid-
ing high-resolution images of  the pancreas without the 
risk of  radiation exposure and identifying mural nodules 
(focal thickening of  the wall in branch duct IPMNs), 
which are associated with increased risk of  malignan-
cy[16,82]. With its high resolution, in experienced hands it 
is able to detect focal lesions as small as 2-5 mm[22,104-106] 
with the possibility of  taking bioptic samples by fine nee-
dle aspiration (FNA) for histopathological examination. 
EUS has been described as a highly sensitive method for 
pancreatic malignancy[107], but results for accuracy differ. 
Early studies have shown a better accuracy in detect-
ing PDAC for EUS compared with dual phase helical 
CT (97% vs 73%, respectively)[108]. This results were also 
confirmed when EUS was compared with multiphase 
helical CT (98% vs 86%, respectively[107,109]. The prospec-
tive CAPS3 study is the first blinded study that compared 
standardized pancreatic protocol CT, secretin-enhanced 
MRI/MRCP and EUS for one-time screening in HRIs. 
It showed that EUS and MRI are better than CT for the 
detection of  small, cystic, pancreatic tumors, with a diag-
genetic analysis[81,84-86].
Mucinous cystic neoplasms
Mucinous cystic neoplasms (MCNs) are cystic epithelial 
neoplasms that occur almost in women, lack of  com-
munication with the pancreatic ductal system and have a 
predilection for the body and tail[80,87]. 
Malignancy rates of  resected MCNs vary from 6% to 
36%[80] and usually resembles common ductal adenocarci-
noma.
Intraductal papillary mucinous neoplasms 
Intraductal papillary mucinous neoplasms (IPMNs) are 
a more aggressive neoplasm compared to MCNs. They 
represent a disorder of  the pancreatic ductal system, 
characterized by cystic dilatation. Clinically, three differ-
ent varieties exist: main duct type characterized by diffuse 
dilatation of  the main pancreatic duct, branch duct type 
(IPMN-BD) appearing as dilatation of  branch ducts, and 
mixed-type involving both of  them.
These lesions are thought to undergo transformation 
from adenoma to borderline neoplasms, and finally to 
carcinoma, similarly as seen with PanINs.
Patients with IPMN-MD have a risk of  malignancy 
of  approximately 50%-90%[16,86-89], vs 6%-46% in patients 
with IPMN-BD[16,87,89,90]. In these patients, the risk of  
malignancy increases with presence of  symptoms, mural 
nodules and size over 3 cm[89]. IPMNs are mainly present 
in familial pancreatic cancer kindred and in PJS and FAP 
patients where seems to have a more aggressive biological 
behavior (increased growth rate and degeneration) com-
pared to sporadic IPMNs[22,91]. IPMNs are more prevalent 
in high risk individuals than in the general population 
(16%-42% vs 0.2%)[92], moreover they are commonest 
in specimens from FPC than in sporadic PDAC (33% vs 
6%)[81].
SCREENING 
The goal of  screening could be the reduction of  pancre-
atic cancer-related mortality. As previously reported, sur-
rogate end point in pancreatic cancer could be the identi-
fication and resection of  potentially curable lesions (high-
grade precursors and early invasive carcinomas). There 
is no evidence that diagnosing these lesions will improve 
survival, but there are data suggesting that resection of  
very early disease is associated with better prognosis[93,94]. 
However, no consensus opinion could be reached on the 
best suitable approach for screening until available imag-
ing modalities and biomarkers will become adequate to 
detect early stage cancer. Actually, serum markers, com-
puted tomography, magnetic resonance (MRI) ± chol-
angiopancreatography (MRCP), endoscopic retrograde 
cholangiopancreatography and endoscopic ultrasound 
haven’t all the features of  an effective screening tool[95-100]. 
Describing the screening modalities is beyond the aim of  
this review. Whatever the approach a surveillance pro-
gram should be recommended for patients with a risk of  
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nostic yield of  42.6%, 33.3% and 11%, respectively[110]. 
EUS was also found to be superior to MRI and CT in 
sensitivity regarding the detection of  IPMN-derived and 
-concomitant PDACs at the first examination (100% vs 
53% and 53% and 61% vs 33% and 39%, respectively) 
and during a 5 years follow-up period (100% vs 50% and 
56%, respectively)[111]. In this setting EUS detected PD-
CAs significantly better than the other modalities and it 
appears to be more useful than CT and MRI for the early 
detection of  pancreatic cancer (Table 2).
Another recent study[112] has shown an incremental 
increase in diagnostic yield of  EUS-FNA over CT (36%) 
and MRI (54%) for prediction of  a neoplastic cyst and 
an increase in overall accuracy for diagnosis of  neoplastic 
pancreatic cysts by the addition of  EUS±FNA.
A normal EUS examination seems to have a high 
negative predictive value (NPV)[113]. Two recent studies 
including patients with suspicion of  pancreatic cancer 
followed for 23.9 and 25 mo, respectively, showed that 
none of  those with a normal EUS evaluation developed 
pancreatic cancer (NPV = 100%)[114,115]. 
Furthermore, EUS-guided fine needle aspiration 
(EUS-FNA) may provide a histological diagnosis of  
cancer and a means of  detecting dysplasia in precancer-
ous lesions[23]. A recent meta-analysis has demonstrated 
that EUS-FNA is highly sensitive (89%), specific (96%), 
accurate (97%) and has a very good positive likelihood 
ratio (16.08) and an acceptable negative likelihood ratio 
(0.13)[116]. Moreover, another recent study not included in 
the meta-analysis previously reported[117], confirmed these 
values and has shown that the diagnostic accuracy of  
EUS-FNA could be further improved by the addition of  
pancreatic juice analysis.
EUS complications are rare and the risk of  perfora-
tion is similar to standard upper endoscopy (< 0.03%). 
Also EUS-FNA of  pancreatic lesions can be considered 
a safe technique, especially if  several technical points 
are taken into account in each specific situation the en-
dosonographer perform a FNA[118]. The two major com-
plications after a FNA are pancreatitis (0%-2%)[119,120] and 
bleeding (0% to 1.3%)[121,122], while the risk of  infection 
exists only when mucinous cystic lesions are involved[118]. 
No deaths were reported[120-123].
Actually, the diagnosis of  PanINs by imaging tests is 
very challenging. The surgical resection of  early curable 
neoplasms detected during screening programs in at-risk 
individuals has permitted to study the morphology of  un-
adulterated precursor lesions in this kind of  patients[21,81]. 
In particular: (1) PanINs are frequently associated with 
lobulocentric atrophy and fibrosis; and (2) PanINs are 
often multifocal.
The combination of  these alterations produces gross-
ly appreciable changes in the pancreas with a mosaic of  
fibrosis, atrophy and uninvolved parenchyma, very similar 
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High risk patients
   ≥ 3 first, second, third-degree relatives with PDAC in the same lineage 
   Known mutation carriers for p16
   Individuals with hereditary pancreatitis
   PJS patients
   Subjects with ≥ 10-fold greater PancPro risk of developing PDAC with respect to the general population
Screening with
   MRI/MRCP or/and EUS ± FNA starting by the age of 40-50 years (30 for PJS) 
   or 10-15 years below the youngest age of onset in family
Suspicious findings
   Small solid tumor
   IPMN
   MCN
   PanIN
Abnormal but not clearly 
suspicious findings Not suspicious findings
Repeat MRI/MRCP or/and EUS ± 
FNA after 1-3 years
Consider surgery
Solid lesion or main 
pancreatic duct stricture Cystic lesion
Consider surgery Repeat MRI/MRCP or/and 
EUS ± FNA after 3-6 mo
Repeat MRI/MRCP or/and 
EUS ± FNA after 6-12 mo
Figure 1  Management algorithm for individuals at risk of pancreatic cancer. EUS: Endoscopic ultrasonography; ERCP: Endoscopic retrograde cholangiopan-
creatography; CT: Computed tomography; FNA: Fine needle aspiration; PDAC: Pancreatic ductal adenocarcinoma; PJS: Peutz-Jeghers syndrome; MRI: magnetic 
resonance imaging; MRCP: Magnetic resonance cholangiopancreatography; IPMN: Intraductal pancreatic mucinous neoplasia; MCN: Mucinous cystic neoplasm; 
PanIN: Pancreatic intraepithelial neoplasia. 
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to chronic pancreatitis[81,124].
These quite subtle ductal and parenchymal changes 
are often detectable by EUS using standard criteria for 
the diagnosis of  chronic pancreatitis, such as heteroge-
neity, multifocal lobularity, echogenic foci, hypoechoic 
nodules, strands and dilated main and branch pancreatic 
ducts[22,124,125].
In literature, chronic pancreatitis-like changes are 
found in variable rates. The John Hopkins group detected 
these findings in 45% and 61% of  the examined HRIs in 
whom they were significantly more common, compared 
with control subjects, regardless of  age and alcohol ex-
posure[22,23]. This ultrasonographic diagnosis of  chronic 
pancreatitis was surgically confirmed in all but one of  
the HRIs who underwent surgery. Furthermore, all but 1 
of  these patients had branch duct-type IPMNs[22]. In the 
University of  Washington study, the authors suggested 
that the pancreatitis-like changes, which are part of  the 
phenotype of  FPC kindreds, are expression of  un under-
lying pancreatic dysplasia rather than chronic pancreati-
tis[21]. Finally the German group reported a relative low 
prevalence (22.4%) with all but one normal findings at 
MRI/MRCP evaluation[103].
These studies suggest that features of  chronic pancre-
atitis should be noted during screening because although 
the precursor lesions may be too small to visualize by 
currently available imaging technologies, the effects they 
produce such as cysts and nodules in a background of  
intact parenchyma, can be detected by EUS in the hands 
of  an experienced operator. 
This was also confirmed in IPMNs. In a recent study 
conducted on forty patients, who underwent resection 
for IPMN, PanIN was researched on surgical speci-
mens and the pathological data were compared with 
endosonography features. EUS changes corresponded to 
PanIN lesions in 83% of  cases and it was able to detect 
69% of  patients with PanIN lesions (57% of  those with 
panIN-3)[126].
Nevertheless, the presence of  a chronic pancreatitis 
drastically reduces the diagnostic value of  EUS, because 
of  the intraductal and parenchymal changes associated 
with chronic inflammation and fibrosis could not to be 
differentiated from premalignant pancreatic lesions[127]. 
In summary the clinical significance of  these changes 
in HRIs remains unclear. They may be indicative of  a 
precursor lesion of  PDAC, but these data must be care-
fully assessed. 
Another field of  application for EUS in HRIs is 
in differentiation between focal pancreatitis and pan-
creatic cancer. Contrast enhanced EUS seems to be a 
promising technique due to perfusion characteristics of  
microvessels[128]. Hocke et al[129] analyzed the sensitivity 
and specificity for the diagnosis of  pancreatic carcinoma 
of  conventional endoscopic B-mode, power Doppler 
ultrasound and contrast-enhanced power mode. They 
reported an increase from 73.2% to 91.1% and from 
83.3% to 93.3% respectively, with the use of  contrast-
enhanced power mode vs conventional EUS. The major 
limits of  EUS are: (1) high interobserver variety, even 
among experienced endosonographers, especially for 
diagnosis of  pancreatitis like changes[130,131]; (2) the need 
for sedation because of  the minimally invasive nature 
of  the procedure; (3) the need of  additional clinical and 
imaging information[112] to improve accuracy as demon-
strated by Meining et al[132] who reported a worse overall 
accuracy for a strictly blinded EUS examinations (61.1%) 
compared to the accuracy of  routine and unblinded 
evaluation with additional imaging information (72.2% 
and 75.0%, respectively); (4) Low sensitivity in case of  
chronic pancreatitis, diffusely infiltrating cancer and a 
recent episode of  acute pancreatitis[133,134]; and (5) Low 
availability outside major centres.
Currently, many international screening protocols are 
available throughout the world and the majority of  them 
use EUS as the main imaging tool for screening, because 
of  its ability to detect masses < 1 cm[21-23,132,135], with CT 
or MRI/MRCP scans and ERCP proposed in combina-
tion with EUS[136].
The first EUS-based screening program was prospec-
tively conducted by Brentnall et al[21] at the Washington 
University, on a small group of  14 high-risk patients from 
three unrelated pancreatic cancer kindred that had two 
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Table 2  Endoscopic ultrasound-based studies on screening for individuals at risk for pancreatic cancer
Ref. No. of patients High-risk groups Imaging test Target lesions Diagnostic yield Limits of the study
Brentnall et al[21] 14 FPC EUS + ERCP + CT PanIN ≥ 2 50%
Kimmey et al[104] 46 FPC EUS PanIN ≥ 2 26%
Canto et al[22] 38 FPC, PJS EUS IPMN, PC 5.30% Low PPV
Canto et al[23] 78 FPC, PJS EUS IPMN, PC, PanIN ≥ 2 10.20%
Poley et al[135] 44 FPC, PJS, 
FAMMM
EUS IPMN, PC 22.70% No pathological confirmation of 
IPMN
Langer et al[103] 76 FPC, FAMMM EUS + MRCP IPMN 1.30% Moderate risk patients
Verna et al[162] 51 FPC, FBOC EUS and/or MRCP IPMN, PC, PanIN ≥ 2 12%
Schneider et al[36] 72 FPC, FAMMM EUS + MRCP IPMN 12.50% No pathological confirmation
Canto et al[110] 216 FPC, FBOC, PJS EUS + CT + MRCP IPMN, PC 39% Mainly no pathological confirmation
FPC: Familial pancreatic cancer; PJS: Peutz-Jeghers syndrome; FAMMM: Familial atypical multiple mole melanoma; FBOC: Familial breast ovarian cancer; 
EUS: Endoscopic ultrasonography; ERCP: Endoscopic retrograde cholangiopancreatography; CT: Computed tomography; MRCP: Magnetic resonance chol
angiopancreatography; PanIN: Pancreatic intraepithelial neoplasia; IPMN: Intraductal pancreatic mucinous neoplasia; PC: Pancreatic cancer; PPV: Positive 
predictive value.
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or more affected members in at least two generations. 
The study evaluates an EUS- and ERCP-based approach 
with the aim to detect pancreatic cancer precursor le-
sions (PanINs). The EUS and ERCP suspected signs of  
PanINs were no specific chronic pancreatitis-like changes. 
Seven patients (50%) had an abnormal EUS and ERCP 
histological confirmed as precancerous changes in the 
pancreas (PanIN-2 and 3) without any invasive cancer. 
A follow up study of  the same group confirmed a 
high yield (26%). It was based on a large cohort of  46 
patients and was conducted using EUS as the first diag-
nostic approach, with ERCP for patients with EUS ab-
normalities. Twelve patients with imaging abnormalities 
were referred to histological examination and all of  them 
revealed widespread precancerous lesions (PanIN 2 e 3), 
without evidence of  invasive pancreatic cancer[136].
Canto et al[23] screened HRIs for early pancreatic neo-
plasia with an EUS-based and an EUS- and CT-based[22] 
prospective controlled study at Johns Hopkins Univer-
sity. In the former approach they used EUS to screen 
38 asymptomatic individuals from high risk families (≥ 
3 affected relatives and PJS). Six pancreatic lesions were 
detected: four benign masses and two neoplastic (one ad-
enocarcinoma and one IPMN; screening yield of  5.3%). 
Either the CT or ERCP evaluations did not detect the 
single PDAC. In the latter one, pancreatic abnormalities 
were compared in 78 high-risk individuals (72 from FPC 
kindred and 6 PJS) and 149 control patients. If  the EUS 
was abnormal, EUS-FNA and ERCP were performed. 
This approach found 8 patients with pancreatic neo-
plasms (10.2%) confirmed by surgery or FNA (6 patients 
had benign IPMNs, 1 had an IPMN with invasive ductal 
adenocarcinoma and 1 patient had PanIN-3) and no pan-
creatic neoplasia among the control subjects. All of  the 
lesions visualized by CT were also detected by EUS, while 
CT missed two IPMNs > 1 cm in the second study and 
one pancreatic cancer in the first one. Moreover, ERCP 
correctly diagnosed only 2 of  the 7 confirmed IPMNs 
seen by EUS.
In contrast to these findings, Langer et al[103] published 
their results of  a prospective screening study conducted 
by the National German Familial Pancreatic Cancer 
Registry (FaPaCa) on 76 individuals from 34 FPC and 
FAMM kindreds. The protocol included CA 19-9 and 
CEA serum values, EUS, and MRI combined with MRCP 
at the screening visit. EUS-FNA was performed in the 
case of  indefinite abnormalities and in case of  diffuse pa-
renchymal irregularities. Only three serous cystoadenoma, 
one IPMN, three PanIN 1 and one PanIN 2 were patho-
logically confirmed. Three of  them, the smaller ones, 
were detected by EUS, but not by MRI. No cancers were 
identified and only IPMN was considered a significant 
precancerous lesion for a diagnostic yield of  1.3%.
This lower yield could be explained by the fact that 
this study included also a large number of  patients at a 
moderate risk (< 10-fold) with a fraction of  high-risk pa-
tients of  42% vs 55% for the second study of  the Johns 
Hopkins University. Moreover, PanIN 1 e 2 and serous 
cystoadenoma were not considered precancerous lesions. 
During long term follow-up[36] (24 mo-extended surveil-
lance), this study showed histologically proven precan-
cerous or cancerous lesions in 4 individuals (5.5%) and 
additional branch duct IPMN in 5 ones, with a diagnostic 
yield of  up to 12.5%, close to the previous rates reported 
by the Johns Hopkins and the Rotterdam groups.
In comparison, Poley et al[135], of  the Dutch group, 
published the results of  a prospective study using EUS 
in 44 asymptomatic high risk family members with FPC, 
BRCA1, BRCA2, or p16 germline mutation carriers, and 
patients with PJS. They found asymptomatic PDAC in 
three patients (6.8%, two with lymph node metastases), 
and seven IPMNs (16%). Their high yield (22.7%) may 
be related to the selection of  known carriers of  muta-
tions at high risk to develop pancreatic cancer with a 
higher fraction of  individuals at elevated risk. 
Nevertheless, it has to be pointed out that IPMNs 
in both German study and in the Dutch study are EUS-
diagnosis, not histologically confirmed. The 12.5% and 
16% results may as well represent overestimations. 
COST EFFECTIVENESS
A screening test can be considered successful if  the ben-
efits/costs ratio is favourable. As previously reported, a 
EUS-based screening allows an early diagnosis of  PDAC, 
while it is not still clear if  this approach could be consid-
ered cost-effectiveness.
Rulyak et al[137] compared one-time EUS-based screen-
ing to no screening in a hypothetical cohort of  100 
members 50 years old of  FPC kindred. The life time 
medical costs and life expectancy were compared, assum-
ing a 20% prevalence of  pancreatic dysplasia and 90% 
sensitivity of  EUS and ERCP. They demonstrated that 
endoscopic screening of  these individuals increases pa-
tient life expectancy (38 years, similar to other common 
preventive medical interventions) in a cost-effective man-
ner ($16885 per life-year saved on the base-case ICER, an 
indicator which take into account the third-part payer and 
the societal perspectives). Only patients with a pre-test 
probability of  pancreatic dysplasia of  16% or greater and 
individuals under 70 years of  age seem to have benefits 
from this approach. Moreover, the sensitivity of  EUS 
and ERCP must be at least 85% in order for screening to 
be effective. The cost-effectiveness of  repeated screening 
was not determined.
In contrast, Rubenstein et al[138] have performed a 
clinical and economic evaluation of  EUS for 45 years-
old male first degree relatives with chronic pancreatitis 
diagnosed by EUS on screening exam. They compared 4 
strategies: do nothing, prophylactic total pancreatectomy, 
EUS and EUS-FNA and assessed mortality, quality of  
life, complications and costs. They addressed the infe-
riority of  EUS compared to a no-screening approach 
because of  the low sensitivity of  EUS in the presence of  
chronic pancreatitis-like changes. EUS-FNA provided in-
termediate results. The prophylactic total pancreatectomy 
could be considered the better approach in terms od life 
expectancy if  the lifetime risk of  pancreatic cancer is 
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46% or greater.
These studies are based on one-time screening and 
so are not applicable to a individuals who require re-
peated screening examinations during their life. A review 
conducted by Latchford et al[139] focused on a cost-effec-
tiveness analysis of  a screening program in PJS, based 
on EUS and ERCP for molecular analysis of  pancreatic 
juice. According to this review, patients with suspicious 
findings would be offered CT, all others should repeat 
screening 1-3 years later, based on risk stratification de-
trmined by molecular tests. With this approach over a 
35-year period of  annual EUS, 3780 screens would be 
carried out and only those with morphological changes 
found on EUS are offered CT and ERCP.
This model can give an estimate of  costs of  about 
$372708 per life saved. This cost could be further re-
duced to $297000 per life saved by molecular analysis 
of  pancreatic juice. In this case, in fact, most individuals 
would only be screened every 3 years thanks to more ac-
curate risk stratification. 
FUTURE PERSPECTIVES
In the near future, the development of  EUS technology 
should help us to screen HRIs.
Contrast-enhanced harmonic endoscopic ultrasonog-
raphy (CH-EUS) visualizes parenchymal perfusion in the 
pancreas without Doppler-related artifacts[140,141]. It could 
play a central role associated to EUS-FNA when the lat-
ter gives a negative finding in a suspected lesion. Two 
recent studies[141,142] showed a higher sensitivity of  CH-
EUS compared to EUS-FNA for the identification of  
pancreatic carcinoma. Most of  false-negative EUS-FNAs 
resulted to have a hypoenhancement on CH-EUS exami-
nation. Moreover, Kitano et al[142] found that CH-EUS 
when combined with EUS-FNA is able to increase the 
sensitivity from 92.2% to 100% and is superior to MDCT 
in diagnosing small (< 2 cm) carcinomas, identifying 9 
tumours missed by MDCT. Fusaroli et al[143] also reported 
that CH-EUS allowed the detection of  small lesions in 
patients with uncertain EUS findings because of  chronic 
pancreatitis. In addition, CH-EUS allows to focus on the 
lesion target for EUS-FNA.
Diagnostic accuracy of  EUS-FNA will be also en-
hanced by the detection of  DNA abnormalities as k-ras 
point mutations and microsatellite losses[144,145] or novel 
protein markers such as mesothelin[146,147] and prostate 
stem cell antigen[147]. Their detection in EUS-FNA speci-
mens may provide confirmation of  the presence or 
absence of  malignancy and should negate the need for 
further testing.
Characterization of  pancreatic cysts has become es-
sential for definitive surgical treatment or ongoing sur-
veillance. However, current diagnostic methods (cross-
sectional imaging, EUS, and fluid analysis including 
cytology, fluid characteristics, chemistry, and tumor mark-
ers) do not allow an accurate differentiation between the 
various types of  cysts[148,149]. A novel needle-based confo-
cal laser endomicroscopy (nCLE) miniprobe that can be 
passed through a 19-G EUS-FNA needle enables real-
time imaging with microscopic detail. A pilot study[150] 
suggests that nCLE can detect mucinous pancreatic neo-
plasms with excellent specificity and PPV (100% for both 
of  them) but a low sensitivity and NPV (59% and 50%, 
respectively) with an overall complication rate of  9%.
Finally, computer-aided diagnostic techniques, yet 
used in some screening programs[151,152], could be added 
to standard EUS images for the differentiation of  pan-
creatic carcinoma from chronic pancreatitis[151,153]. With 
digital image processing and computer-aided EUS image 
differentiation technologies, physicians could use the 
computer output as a ‘‘second opinion’’ and make the fi-
nal decisions as reported by the high diagnostic accuracy 
(98%) of  a recent study[154]. 
CONCLUSION
These data demonstrate that screening with EUS, prefer-
ably associated with MRCP, as reported by International 
Cancer of  the Pancreas Screening summit (83.7% agree 
for EUS and 73.5% agree for MRI/MRCP)[96] is feasible 
and can detect curable pancreatic neoplasms in correctly 
identified asymptomatic at-risk patients. In particular, as 
reported by Ludwig et al[155], EUS could be subsequent to 
an MRCP as initial imaging. This approach should reduce 
the number of  false positives (patients with abnormal 
MRCPs who on EUS had no appreciable lesion) avoiding 
unnecessary surgery. The two modalities may comple-
ment each other. In fact, MRI/MRCP, in contrast with 
EUS, is able to image the entire abdomen and pelvis, an 
useful feature for patients at risk for multi-organ cancer, 
but has a low sensitivity in detecting PanIN lesions and 
small (< 1 cm) pancreatic cancer, even if  recently there 
has been the development of  3T MRI scanners able to 
detects small tumors in asymptomatic patients through 
indirect signs (black and white sign) and cystic lesions ≥ 
3 mm[99,156]. MRCP is superior to EUS in delineating le-
sions involving the pancreatic ductal system[97,98] even if  
a recent study[157] has shown similar results between three 
dimensional CEUS and MRI in evaluating IPMNs small-
er than 1 cm. Nevertheless EUS can image mural nodules 
associated with increased risk of  malignancy.
It is also strongly suggested that surveillance pro-
grams should be performed by a center with experience 
in the specific pathology within the context of  peer 
reviewed protocols to reduce interobserver disagree-
ment[100]. 
Indeed, EUS is an operator-dependent technique that 
requires considerable skills and training in EUS is essen-
tial to gain experience to reliably examine the pancreas. 
The intensity and length of  training, the requisite curricu-
lum and the minimum number of  procedures required to 
ensure competency are not well-defined[158].
Some experts recommend a minimum of  75 pancrea-
tobiliary procedures and 25 cases of  pancreatic FNA[159], 
others suggest a minimum of  30 supervised EUS-FNA 
279 July 16, 2014|Volume 6|Issue 7|WJGE|www.wjgnet.com
Lami G et al . EUS for surveillance of pancreatic cancer
on pancreatic lesions[160] while someones believe that 
the majority of  trainees will require double the number 
of  proposed procedures to achieve competency in 
EUS[161,162]. 
An extensive use of  CT or ERCP should be avoided 
in screening programs that require repeated exams in 
healthy individuals who have only a statistical risk of  can-
cer.
However, a number of  questions remain to be an-
swered. What are the significance and natural history of  
EUS-detected chronic pancreatitis-like abnormalities? 
What is the clinical significance of  PanIN with moder-
ate dysplasia? Should it always be treated with pancre-
atectomy? How to manage the IPMN-like cystic lesions 
frequently found in HRIs? Should be offered surgery or a 
wait-and-see policy can be adopted?
As the resolution of  imaging improves and as our 
knowledge of  precursor lesions grows, we believe that 
these questions will be answered in the future.
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